KR900700134A - Il-2 수용체-특이적 키메릭 항체 - Google Patents

Il-2 수용체-특이적 키메릭 항체

Info

Publication number
KR900700134A
KR900700134A KR1019890702368A KR890702368A KR900700134A KR 900700134 A KR900700134 A KR 900700134A KR 1019890702368 A KR1019890702368 A KR 1019890702368A KR 890702368 A KR890702368 A KR 890702368A KR 900700134 A KR900700134 A KR 900700134A
Authority
KR
South Korea
Prior art keywords
human
region
cell line
immunoglobulin
chimeric antibody
Prior art date
Application number
KR1019890702368A
Other languages
English (en)
Inventor
퀸 캐리.엘
Original Assignee
원본미기재
프로테인 디자인 랩스, 인코오포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 프로테인 디자인 랩스, 인코오포레이티드 filed Critical 원본미기재
Publication of KR900700134A publication Critical patent/KR900700134A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

내용 없음

Description

IL-2 수용체-특이적 키메릭 항체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 항-TaC 경사슬의 V 및 J지역의 DNA암호 서열 및 추정 아미노산 서열을 도시하며, 제2도는 항-TaC 중 사슬V 및 J지역의 DNA암호 서열 및 추정 아미노산 서열을 도시한 것이며, 제3-10도는 본 발명을 입증하기 위해 사용된 플라스미드의 기계적 다이아그램.

Claims (30)

  1. 인간 T-세포상에서 IL-2수용체와 특이적으로 반응하는 쥐의 가변성/인간 고정지역 키메릭 항체 조성물의 치료적 유효량을 환자에게 투여하여 인간 환자의 T-세포 조절에 의한 질환을 치료하는 방법.
  2. 제1항에 있어서, 쥐의 가변성 지역은 A.T.C.C 제 CRL 9688호로 기탁된 세포주에 의해 생산된 항-TaC단클론의 중사슬 및 경사슬로부터 가변성 지역 전체를 함유하는 방법.
  3. 제1항에 있어서, 쥐의 가변성 지역중 하나가 지역발생의 쥐의 J단편과 결합하는 방법.
  4. 제1항에 있어서, 인간 경사슬 고정 지역은 k사슬 고정지역을 포함하는 방법.
  5. 제1항에 있어서, 인간 경사슬 지역은 8 또는 8사슬 고정지역을 포함하는 방법.
  6. 제1항에 있어서, 조성물은 세포 독성제와 복합된 키메릭항체를 포함하는 방법.
  7. 제1항에 있어서, 세포 독성제는 프로테인을 억제하는 리보조말, 조사 뉴클라이드 또는 세포 독성 계면활성제인 방법.
  8. 항체는 두쌍의 경사슬/중사슬 복합체를 지니며, 적어도 하나의 쌍은 쥐의 가변성 지역 및 인간의 고정지역 단편을 함유하며, 인간의 IL-2 수용체 에피토프에 결합할 수 있는 키메릭 항체.
  9. 제8항에 있어서, 쥐의 가변성 지역은 자연발생의 J-단편에 근접하는 키메릭 항체.
  10. 제8항에 있어서, A.T.C.C 기탁번호 CRL 9688 호로 기탁된 세포주에 분비되는 단클론 항체 결합을 억제하는 키메릭 항체.
  11. 제10항에 있어서, 적어도 하나의 가변성 지역은 항-TaC단클론 항체의 가변성 지역의 아미노산 서열을 함유하는 키메릭 항체.
  12. 제8항에 있어서, 골수종 또는 하이브리도마 세포중에서 생산되는 키메릭 항체.
  13. 제8항에 있어서, 인간의 개놈성 DNA단편에 결합된 쥐의 cDNA단편을 함유하는 트랜스팩트된 DNA서열로부터 골수종 세포중에서 형질 발현되는 키메릭 항체.
  14. 제8항에 있어서, 세포독성제 또는 시그날 반응제와 복합되는 키메릭 항체.
  15. A.T.C.C 기탁번호 제 CRL 9688호로 기탁된 세포주에 의해 분비된 단클론 항체 중 사슬 가변성 지역과 거의 동일한 인간 중사슬 고정 지역 및 가변성 사슬 지역을 함유하는 면역 글로블린 중사슬.
  16. 제15항에 있어서, 가변성 및 고정 지역을 쥐의 J단편에 의해 결합된 면역 글로블린 중사슬.
  17. A.T.C.C 기탁번호 제 CRL 9688호로 기탁된 세포주에 의해 분비된 단클론 항체 경사슬 가변성 지역에 거의 동일한 인간 경사슬 고정지역 및 가변성 지역 함유의 면역 클로블린 경사슬.
  18. 인간 면역 글로블린 고정지역을 암호하는 첫번째 서열과 쥐의 인간 면역 글로블린 가변성 지역을 함유하는 두번째 지역으로 구성되고, 두번째 서열이 제1도또는 제2도의 아미노산 서열중 거의 하나를 암호하는 폴리뉴클레오티드 분자.
  19. 제18항의 폴리뉴클레오티드로 트랜스팩트된 세포주.
  20. A.T.C.C 기탁번호 제 CRL 9688호로 기탁된 세포주.
  21. 면역 글로블린 경사슬 일부를 암호하며, 제1도 서열로부터 적어도 약 30의 연속 뉴클레오티드를 함유하는 DNA단편.
  22. 제21항에 있어서, 단편은 제1도 서열과 거의 동일한 전체 길이의 경사슬 가변성 지역을 암호하는 DNA단편.
  23. 면역 글로블린 중사슬 일부를 암호하며, 제2도 서열로 부터 적어도 약 30의 연속 뉴클레오티드를 함유하는 DNA단편.
  24. 제23항에 있어서, 단편은 제2도의 단편과 실질적으로 동일한 전체 길이의 중사슬 가변성 지역을 암호하는 DNA.
  25. 제21항 또는 제 23항에 따른 DNA단편에 결합된 이형 프로모터를 함유하는 형질 발현 벡터.
  26. 제25항에 따른 형질 발현 형질 변형된 영구세포주.
  27. 이형 폴립펩티드에 융합된 제1도 또는 제2도의 프로테인 서열로부터 적어도 약 10개의 연속 아미노산 함유의 프로테인 조성물.
  28. 제27항에 있어서, 이형 폴리 펩티드는 면역 글로블린 고정 지역인 프로테인 조성물.
  29. 제 27항에 있어서, 프로테인이 글로코실화된 프로테인 조성물.
  30. A.T.C.C 기탁번호 제 CRL 9688호로 기탁된 세포주에 의해 분리된 면역 글로블린으로서 거의 동일한 항원결합 프로필을 나타내는 제조합 생산항체.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890702368A 1988-04-15 1989-04-13 Il-2 수용체-특이적 키메릭 항체 KR900700134A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18186288A 1988-04-15 1988-04-15
US181,862 1988-04-15
PCT/US1989/001578 WO1989009622A1 (en) 1988-04-15 1989-04-13 Il-2 receptor-specific chimeric antibodies

Publications (1)

Publication Number Publication Date
KR900700134A true KR900700134A (ko) 1990-08-11

Family

ID=22666118

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890702368A KR900700134A (ko) 1988-04-15 1989-04-13 Il-2 수용체-특이적 키메릭 항체

Country Status (6)

Country Link
EP (1) EP0362371A4 (ko)
JP (1) JPH02503867A (ko)
KR (1) KR900700134A (ko)
AU (1) AU631545B2 (ko)
FI (1) FI895955A0 (ko)
WO (1) WO1989009622A1 (ko)

Families Citing this family (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
PT92900A (pt) * 1989-01-24 1990-07-31 Sistema de vectores de expressao para a producao de anticorpos monoclonais quimericos
FR2649488A1 (fr) * 1989-07-07 1991-01-11 Inst Nat Sante Rech Med Fragments d'anticorps monoclonaux specifiques de la presence de leucocytes actives - leur procede d'obtention et leur application dans le cas de rejet de greffe
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US5196320A (en) * 1989-09-20 1993-03-23 Abbott Biotech, Inc. Method of producing engineered binding proteins
FR2652746A1 (fr) * 1989-10-06 1991-04-12 Merieux Inst Application d'agents actifs pour la preparation d'un medicament destine au traitement de lymphomes ou assimiles.
FR2652747B1 (fr) * 1989-10-06 1995-03-31 Merieux Inst Application d'agents actifs pour la preparation d'un medicament destine au traitement de maladies auto-immunes.
GR1001050B (el) * 1990-01-09 1993-04-28 Protein Design Labs Inc Νεος il-2 υποδοχευς ιδιαζοντων ανθρωπινων ανοσοσφαιρινων.
HUT60768A (en) * 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
DE4018442A1 (de) * 1990-06-08 1991-12-12 Boehringer Mannheim Gmbh Rekombinante dna und verfahren zur herstellung chimaerer antikoerper
DE4028955A1 (de) 1990-09-12 1992-03-19 Boehringer Mannheim Gmbh Monoklonale antikoerper gegen den interleukin 2-rezeptor
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5837491A (en) * 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
US6146850A (en) * 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
US5621083A (en) * 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US5766886A (en) * 1991-12-13 1998-06-16 Xoma Corporation Modified antibody variable domains
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
DE19543039C1 (de) * 1995-11-08 1996-11-21 Medac Klinische Spezialpraep Rekombinante Liganden für das menschliche Zellmembran-Antigen CD30
JP4344404B2 (ja) 1996-02-09 2009-10-14 アムジェン インコーポレイテッド インターロイキン―１インヒビターおよび制御放出ポリマーを含む組成物
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
DE69738948D1 (de) 1996-12-06 2008-10-09 Amgen Inc Il-1-inhibitor in kombinationstherapie zur behandlung il-1-vermittelter krankheiten
EP1724282B1 (en) 1997-05-21 2013-05-15 Merck Patent GmbH Method for the production of non-immunogenic proteins
PT1100829E (pt) * 1998-07-27 2007-12-06 Univ London Utilização de moléculas de ligação à cd25 no tratamento de artrite reumatóide e doenças cutâneas
JP2003520195A (ja) 1999-05-14 2003-07-02 イムクローン システムズ インコーポレイティド 上皮成長因子受容体アンタゴニストによる難治性ヒト腫瘍の処理
WO2001002853A2 (en) 1999-07-05 2001-01-11 K.U. Leuven Research & Development DETECTION OF VON-WILLEBRANDFACTOR (vWF) ACTIVITY
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
US7071319B2 (en) 2000-05-16 2006-07-04 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
IL152825A (en) 2000-05-16 2009-07-20 Univ Jefferson Rabies virus-specific neutralizing human monoclonal antibodies and nucleic acids and related methods
CA2438652A1 (en) 2001-02-19 2002-09-06 Merck Patent Gesellschaft Mit Beschraenkter Haftung Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
JP2005535636A (ja) 2002-06-28 2005-11-24 アメリカ合衆国 インターフェロンβおよびＩＬ−２Ｒアンタゴニストを用いて自己免疫疾患を治療する方法
DK2308507T3 (da) 2002-07-19 2015-04-20 Beth Israel Hospital Fremgangsmåder til behandling af præeklampsi
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
EP1660535A2 (en) 2002-11-27 2006-05-31 Minerva Biotechnologies Corporation Techniques and compositions for the diagnosis and treatment of cancer (muc1)
WO2005016970A2 (en) 2003-05-01 2005-02-24 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
DK1694706T3 (da) 2003-11-01 2012-07-16 Merck Patent Gmbh Modificeret anti-CD52-antistof
ES2324538T3 (es) 2003-12-05 2009-08-10 Multimmune Gmbh Anticuerpos anti-hsp terapeuticos y de diagnostico.
CA2560305C (en) 2004-03-19 2016-07-05 Imclone Systems Incorporated Human anti-epidermal growth factor receptor antibody
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
US8492106B2 (en) 2004-05-24 2013-07-23 Universitat Zu Koln Identification methods for ergothioneine transporter modulators and therapeutic uses thereof
EP1602926A1 (en) 2004-06-04 2005-12-07 University of Geneva Novel means and methods for the treatment of hearing loss and phantom hearing
DK1784220T3 (en) 2004-08-26 2018-03-19 Univ Western Ontario BACTERIAL OBJECTIVES TO ACHIEVE IRON
CA2581336C (en) 2004-09-24 2022-10-04 S. Ananth Karumanchi Diagnosis of pregnancy-related hypertensive disorder by measurement of soluble endoglin
EP1797127B1 (en) 2004-09-24 2017-06-14 Amgen Inc. Modified fc molecules
CN102397542B (zh) 2004-11-18 2014-05-07 英克隆有限责任公司 抗血管内皮生长因子受体-1的抗体
EP1812064A4 (en) 2004-11-19 2009-07-08 Cornell Res Foundation Inc USE OF ENDOTHELIAL VASCULAR GROWTH FACTOR RECEPTOR CELLS IN THE TREATMENT AND MONITORING OF CANCER AND IN THE SCREENING OF CHEMOTHERAPEUTIC AGENTS
CA2610292C (en) 2005-03-30 2015-06-02 Minerva Biotechnologies Corporation Proliferation of muc1 expressing cells
DK1875244T3 (en) 2005-03-30 2019-04-29 Minerva Biotechnologies Corp Proliferation of MUC1-Expressing Cells
EP1712557A1 (en) 2005-04-14 2006-10-18 RWTH Aachen New s-adenosyl-L-methionine analogues with extended activated groups for transfer by methyltransferases
BRPI0611984A2 (pt) 2005-06-17 2009-07-07 Imclone Systems Inc uso de anticorpos igf-ir para fabricação de um medicamento para tratar um tumor ósseo
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
BRPI0617057A2 (pt) 2005-08-30 2011-07-12 Univ Miami anticorpo isolado, toxina especìfica para receptor de fator de necrose tumoral 25 (tnfr25), método para ativar o receptor de fator de necrose tumoral 25 (tnfr25), método para inibir a sinalização do receptor de fator de necrose tumoral 25 (tnfr25) numa célula, vacina antitumoral, método para imunizar um paciente contra tumor, método para tratar cáncer num paciente, método para tratar e/ou prevenir inflamação intestinal, composição terapêutica para a facilitação de um transplante de órgão, método para transplantar um tecido de um doador para um hospedeiro, método para inibir a expressão clonal de uma população de células t cd8 cognatas, método para tratar e/ou prevenir inflamação pulmonar, antagonista de tnfr25 isolado, composição e vetor de expressão
AU2007274738B2 (en) 2006-07-18 2013-11-28 Sanofi-Aventis Antagonist antibody against EphA2 for the treatment of cancer
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2094733A1 (en) 2006-11-03 2009-09-02 U3 Pharma GmbH Fgfr4 antibodies
PT2099826E (pt) 2007-01-05 2014-01-09 Univ Zuerich Anticorpo anti-beta-amilóide e suas utilizações
ES2637214T3 (es) 2007-03-13 2017-10-11 Universität Zürich Anticuerpo monoclonal humano específico para cada tumor
WO2008118324A2 (en) 2007-03-26 2008-10-02 Macrogenics, Inc. Composition and method of treating cancer with an anti-uroplakin ib antibody
KR100883430B1 (ko) 2007-06-13 2009-02-12 한국생명공학연구원 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
US20090010966A1 (en) 2007-06-21 2009-01-08 Angelica Therapeutics, Inc. Modified diphtheria toxins
UA117446C2 (uk) 2007-08-29 2018-08-10 Санофі-Авентіс Гуманізоване антитіло до cxcr5
EP2527369A3 (en) 2007-09-13 2012-12-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
EP2918605A1 (en) 2007-11-12 2015-09-16 U3 Pharma GmbH Axl antibodies
AU2009222998B2 (en) 2008-03-12 2013-05-23 Imclone Llc Anti-TYRP1 antibodies
AR071891A1 (es) 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
US8163497B2 (en) 2008-09-07 2012-04-24 Glyconex Inc. Anti-extended type I glycosphingolipid antibody, derivatives thereof and use
WO2010042891A2 (en) 2008-10-09 2010-04-15 Minerva Biotechnologies Corporation Method for inducing pluripotency in cells
MX2011006422A (es) 2008-12-19 2011-09-15 Panima Pharmaceuticals Ag Autoanticuerpos humanos anti-alfa-sinucleina.
AU2010280981B2 (en) 2009-08-05 2016-01-28 Nexigen Gmbh Human HCV-interacting proteins and methods of use
WO2011022472A2 (en) 2009-08-18 2011-02-24 President And Fellows Of Harvard College Methods and compositions for the treatment of proliferative and pathogenic diseases
WO2011024114A1 (en) 2009-08-25 2011-03-03 Ecole Polytechnique Federale De Lausanne (Epfl) Targeting extracellular matrix molecules for the treatment of cancer
EP2305285A1 (en) 2009-09-29 2011-04-06 Julius-Maximilians-Universität Würzburg Means and methods for treating ischemic conditions
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
PT3295957T (pt) 2010-01-15 2019-11-12 Kirin Amgen Inc Formulação de anticorpo anti il-17ra e regimes terapêuticos para o tratamento de psoríase
MX341687B (es) 2010-02-10 2016-08-30 Immunogen Inc "anticuerpos cd20 y su utilización".
CN102844050B (zh) 2010-02-19 2019-02-05 康奈尔大学 自身免疫性脱髓鞘疾病及其它自身免疫疾病或炎性疾病的治疗方法
AR080698A1 (es) 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
WO2011145085A2 (en) 2010-05-21 2011-11-24 Procognia (Israel) Ltd Novel antibodies and methods of use for the treatment and diagnosis of cancer
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
EP2609431B1 (en) 2010-08-27 2017-05-10 University of Zurich Method for target and drug validation in inflammatory and/or cardiovascular diseases
WO2012028697A1 (en) 2010-09-01 2012-03-08 Eth Zürich, Institute Of Molecular Biology And Biophysics Affinity purification system based on donor strand complementation
HUE058896T2 (hu) 2010-10-01 2022-09-28 Modernatx Inc N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai
US8940272B2 (en) 2010-10-11 2015-01-27 University Of Zurich Human anti-tau antibodies
JP5995851B2 (ja) 2010-10-18 2016-09-21 メディアファーマ エス． アール． エル．Ｍｅｄｉａｐｈａｒｍａ Ｓ． Ｒ． Ｌ． ＥｒｂＢ３結合抗体
EP2651979B1 (en) 2010-12-17 2019-08-28 Neurimmune Holding AG Human anti-sod1 antibodies
WO2012104824A1 (en) 2011-02-04 2012-08-09 Ecole polytechnique fédérale de Lausanne (EPFL) Therapeutic antibodies targeting app-c99
WO2012113775A1 (en) 2011-02-21 2012-08-30 University Of Zurich Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders
EP3235508B1 (en) 2011-03-16 2020-12-30 Sanofi Compositions comprising a dual v region antibody-like protein
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
EP2530088A1 (en) 2011-05-30 2012-12-05 Klinikum rechts der Isar der Technischen Universität München Means and methods for diagnosing and treating multiple sclerosis
EA030777B9 (ru) 2011-06-23 2019-02-28 Байоджен Интернэшнл Нейросайенз Гмбх Анти-альфа-синуклеинсвязывающие молекулы
DE202011103324U1 (de) 2011-07-12 2012-01-02 Nekonal S.A.R.L. Therapeutische anti-TIRC7 Antikörper für die Verwendung in Immun und anderen Krankheiten
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2758433B1 (en) 2011-09-19 2017-10-18 Axon Neuroscience SE Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
US20140248294A1 (en) 2011-10-05 2014-09-04 University Of Bremen Wnt4 and med12 for use in the diagnosis and treatment of tumor diseases
JP6466170B2 (ja) 2011-10-17 2019-02-06 ミネルバ バイオテクノロジーズ コーポレーション 幹細胞の増殖及び誘導用の培地
EP2602621A1 (en) 2011-12-08 2013-06-12 Julius-Maximilians-Universität Würzburg LASP-1, a novel urinary marker for transitional cell carcinoma detection
EP2791160B1 (en) 2011-12-16 2022-03-02 ModernaTX, Inc. Modified mrna compositions
EP2794660A2 (en) 2011-12-23 2014-10-29 Phenoquest AG Antibodies for the treatment and diagnosis of affective and anxiety disorders
CA2861793C (en) 2011-12-28 2023-08-01 Immunoqure Ag Method of providing monoclonal auto-antibodies with desired specificity
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
CN103382223B (zh) 2012-04-01 2015-06-10 上海益杰生物技术有限公司 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243951A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
ES2785274T3 (es) 2012-07-05 2020-10-06 Univ Pennsylvania La RNPsn U1 regula la expresión génica y modula la oncogenicidad
WO2014039513A2 (en) 2012-09-04 2014-03-13 The Trustees Of The University Of Pennsylvania Inhibition of diacylglycerol kinase to augment adoptive t cell transfer
EP2711016A1 (en) 2012-09-21 2014-03-26 Covagen AG Novel IL-17A binding molecules and medical uses thereof
DE102012020496A1 (de) 2012-10-18 2014-04-24 Charité - Universitätsmedizin Berlin Biomarker zur Diagnostik und Behandlung von Neurofibromatose Typ 1
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
KR102234324B1 (ko) 2012-12-21 2021-03-31 바이오젠 엠에이 인코포레이티드 인간 항-타우 항체
EP3517545A1 (en) 2012-12-31 2019-07-31 Neurimmune Holding AG Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
US10059750B2 (en) 2013-03-15 2018-08-28 Angelica Therapeutics, Inc. Modified toxins
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CN107460201A (zh) 2013-05-08 2017-12-12 科济生物医药（上海）有限公司 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
CA2917112C (en) 2013-07-03 2022-07-05 Immunoqure Ag Human anti-ifn-alpha antibodies
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
CN104774264B (zh) 2014-01-15 2018-09-14 上海易乐生物技术有限公司 抗人proBDNF单克隆抗体及其在疼痛中的作用
AU2015241373B2 (en) 2014-03-31 2020-11-05 Amgen K-A, Inc. Methods of treating nail and scalp psoriasis
ES2750648T3 (es) 2014-04-30 2020-03-26 Klinikum Rechts Der Isar Der Technischen Univ Muenchen Diagnóstico de esclerosis múltiple
TW201628647A (zh) 2014-06-27 2016-08-16 賽諾菲公司 抗－ｉｌ４－ｉｌ１３雙特異性抗體
CN112979828A (zh) 2014-07-17 2021-06-18 恺兴生命科技(上海)有限公司 靶向cld18a2的t淋巴细胞及其制备方法和应用
GB201415349D0 (en) 2014-08-29 2014-10-15 Univ Leuven Kath Cofactor analogues for methyltransferases
MX2017004213A (es) 2014-09-30 2017-07-19 Neurimmune Holding Ag Anticuerpo anti-repeticiones de dipeptido (dpr) derivados de humano.
WO2016081796A1 (en) 2014-11-21 2016-05-26 Yale University Compositions and methods for modulating salm5 and hvem
MA41629A (fr) 2015-03-04 2018-01-09 Center For Human Reproduction Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité
US10711054B2 (en) 2015-03-16 2020-07-14 Helmholtz Zentrum München—Deutsches Forschungszentrum fur Gesundheit und umwelt (GmbH) Trispecific binding molecules for treating HBV infection and associated conditions
JP2018516230A (ja) 2015-03-18 2018-06-21 ザ・ジョンズ・ホプキンス・ユニバーシティ カリウムチャネルｋｃｎｋ９を標的とする新規モノクローナル抗体阻害剤
ITUB20155097A1 (it) 2015-11-05 2017-05-05 Biouniversa Srl Anticorpi umanizzati anti-BAG3
EP3202788A1 (en) 2016-02-05 2017-08-09 MediaPharma S.r.l. Endosialin-binding antibody
ITUA20162242A1 (it) 2016-04-01 2017-10-01 St Biochimico Italiano Giovanni Lorenzini Spa Un nuovo anticorpo anti-erbb2
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
US10316037B1 (en) 2016-11-04 2019-06-11 Yale University Compounds and methods for treating cancer
IT201600111877A1 (it) 2016-11-07 2018-05-07 Biouniversa Srl Anti-BAG3 antibodies in combination with inhibitors of immune check-point for therapeutic use
US20180230218A1 (en) 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
US11773182B2 (en) 2017-01-05 2023-10-03 The Johns Hopkins University Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA)
TWI808963B (zh) 2017-03-22 2023-07-21 法商賽諾菲公司 使用人類化抗ｃｘｃｒ５抗體治療狼瘡
US10722589B2 (en) 2017-04-03 2020-07-28 Covagen Ag FGFR3 binding molecules
WO2019207159A1 (en) 2018-04-27 2019-10-31 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
WO2019217450A1 (en) 2018-05-08 2019-11-14 Rhode Island Hospital Anti-chi3l1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatohepatitis and subsequent complications
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
WO2020053808A1 (en) 2018-09-12 2020-03-19 Georg Dewald Method of diagnosing vasoregulatory disorders
WO2020099235A1 (en) 2018-11-12 2020-05-22 Mediapharma S.R.L. Bispecific antibodies directed against human 90k and either endosialin or her3
CA3125697A1 (en) 2019-01-29 2020-08-06 Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) Treating the causative agent in adhesiogenesis
JP2022520088A (ja) 2019-02-13 2022-03-28 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 抗末梢リンパ節アドレッシン抗体およびその使用
US11827671B2 (en) 2019-05-24 2023-11-28 Sanofi Methods for treating systemic sclerosis
WO2021140173A1 (en) 2020-01-10 2021-07-15 Biouniversa S.R.L. Methods and uses for treating fibrotic solid tumors with bags inhibitors
IL296241A (en) 2020-03-10 2022-11-01 Massachusetts Inst Technology Compositions and methods for immunotherapy for npm1c-positive cancer
WO2022189632A1 (en) 2021-03-12 2022-09-15 Fibrosys S.R.L. Monoclonal antibodies for the treatment of viral infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US664911A (en) * 1900-09-17 1901-01-01 William H Voss Mechanical movement.
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
EP0173494A3 (en) * 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
JPS61134325A (ja) * 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB2188941B (en) * 1986-04-14 1990-06-06 Bayer Ag Monoclonal antibodies recognizing human interleukin-2-receptor

Also Published As

Publication number Publication date
JPH02503867A (ja) 1990-11-15
WO1989009622A1 (en) 1989-10-19
AU3544589A (en) 1989-11-03
EP0362371A4 (en) 1990-10-24
EP0362371A1 (en) 1990-04-11
FI895955A0 (fi) 1989-12-13
AU631545B2 (en) 1992-12-03

Similar Documents

Publication Publication Date Title
KR900700134A (ko) Il-2 수용체-특이적 키메릭 항체
EP0347433B1 (en) Recombinant antibody
Olafsen et al. Characterization of engineered anti-p185HER-2 (scFv-CH3) 2 antibody fragments (minibodies) for tumor targeting
JPH05502384A (ja) 抗体の調製
KR910700350A (ko) Il-2수용체의 p_55 tac 단백질에 대해 특이적인 키메릭 면역글로블린
DE69412614T2 (de) Recombinante disulfid-stabilisierte polypeptide mit bindung spezifität
EP0486652A1 (en) Multivalent antigen-binding proteins
Nissim et al. Mapping of the high affinity Fc epsilon receptor binding site to the third constant region domain of IgE.
JPH03501440A (ja) 免疫反応性ヘテロ鎖抗体
CA2263106A1 (en) Humanized immunoglobulin reactive with .alpha.4.beta.7 integrin
KR950701386A (ko) 레스피라토리 신시티알 바이러스 감염증의 치료 및 예방용 항체(Antibodies For Treatment And Prevention Of Resipiratory Syncytial Virus infection)
RU96109042A (ru) Рекомбинантные il4 антитела, используемые для лечения нарушений, связанных с действием il4
Humphreys et al. F (ab′) 2 molecules made from Escherichia coli produced Fab′ with hinge sequences conferring increased serum survival in an animal model
Nicola et al. Neutralizing and nonneutralizing monoclonal antibodies to the human granulocyte-macrophage colony-stimulating factor receptor alpha-chain
KR970070198A (ko) 항-파스 재조합 항체 및 이에 대한 디엔아이
US20230322950A1 (en) Antigen binding receptors
Olafsen et al. IgM secretory tailpiece drives multimerisation of bivalent scFv fragments in eukaryotic cells
Santos et al. Generation and characterization of a single gene-encoded single-chain-tetravalent antitumor antibody
KR920701441A (ko) Hiv 항원에 특이성을 가지는 키메릭 마우스 인간 항체
Mizutani et al. Effector functions of a mouse IgG that lacks the entire CH1 domain. C1q binding and complement fixation in the absence of antigen.
Laroche-Traineau et al. Analysis of the V genes coding for a monospecific human antibody to myosin and functional expression of single chain Fv fragments
Wines et al. The Fab/c fragment of IgG produced by cleavage at cyanocysteine residues
CN110662560A (zh) 改进的抗原结合受体

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid